Aberdeen Group plc Sells 9,919 Shares of Tarsus Pharmaceuticals, Inc. $TARS

Aberdeen Group plc trimmed its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 16.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 51,678 shares of the company’s stock after selling 9,919 shares during the quarter. Aberdeen Group plc owned 0.12% of Tarsus Pharmaceuticals worth $3,071,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of TARS. Osaic Holdings Inc. grew its stake in Tarsus Pharmaceuticals by 779.1% in the second quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock valued at $113,000 after purchasing an additional 2,462 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Tarsus Pharmaceuticals by 220.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,045 shares of the company’s stock valued at $164,000 after acquiring an additional 2,782 shares in the last quarter. West Wealth Group LLC purchased a new stake in Tarsus Pharmaceuticals during the third quarter worth $202,000. Valeo Financial Advisors LLC acquired a new position in Tarsus Pharmaceuticals in the 3rd quarter worth about $209,000. Finally, Allianz Asset Management GmbH acquired a new stake in shares of Tarsus Pharmaceuticals in the second quarter valued at about $227,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, insider Dianne C. Whitfield sold 7,397 shares of the firm’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total value of $592,499.70. Following the completion of the transaction, the insider owned 38,958 shares in the company, valued at $3,120,535.80. This trade represents a 15.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Bobak R. Azamian sold 6,000 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Wednesday, December 24th. The stock was sold at an average price of $82.51, for a total value of $495,060.00. Following the transaction, the chief executive officer owned 857,991 shares of the company’s stock, valued at $70,792,837.41. This represents a 0.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 8.97% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

TARS has been the subject of a number of recent research reports. The Goldman Sachs Group reiterated a “neutral” rating and issued a $68.00 target price on shares of Tarsus Pharmaceuticals in a research report on Thursday, February 5th. Wall Street Zen upgraded shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Guggenheim increased their price target on shares of Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Barclays began coverage on Tarsus Pharmaceuticals in a research note on Monday, December 8th. They issued an “overweight” rating and a $100.00 price objective for the company. Finally, Mizuho assumed coverage on Tarsus Pharmaceuticals in a report on Thursday, November 20th. They set an “outperform” rating and a $100.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Tarsus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $82.29.

Tarsus Pharmaceuticals Stock Up 1.6%

Tarsus Pharmaceuticals stock opened at $66.61 on Friday. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.29 and a quick ratio of 4.25. Tarsus Pharmaceuticals, Inc. has a 1-year low of $38.51 and a 1-year high of $85.25. The stock’s 50 day moving average price is $72.54 and its 200 day moving average price is $67.64. The company has a market cap of $2.83 billion, a PE ratio of -32.98, a price-to-earnings-growth ratio of 0.95 and a beta of 0.57.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.